Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Trudel · SciRah

Researcher profile · Semantic Scholar

S. Trudel

Share profile

S. Trudel — researcher profile on SciRah

h-index: 54
Works: 402
Citations: 12K

Most-cited papers

Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.
M. Dimopoulos, M. Beksaç, L. Pour, S. Delimpasi +18 more
2024New England Journal of Medicine153 citations
Semantic Scholar
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
N. Bahlis, Caitlin L. Costello, N. Raje, M. Levy +15 more
2023Nature Medicine143 citations Open access
Semantic Scholar
Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes
Sheri Skerget, Daniel A. Peñaherrera, A. Chari, Sundar Jagannath +124 more
2024Nature Genetics82 citations Open access
Semantic Scholar
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.
P. Richardson, S. Trudel, R. Popat, M. Mateos +27 more
2023New England Journal of Medicine70 citations Open access
Semantic Scholar
Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study
A. Lesokhin, J. Richter, S. Trudel, A. Cohen +17 more
2022Blood70 citations Open access
Semantic Scholar
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial
A. Nooka, Adam D. Cohen, Hans C. Lee, A. Badros +20 more
2023Cancer58 citations Open access
Semantic Scholar
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration
K. Anderson, D. Auclair, S. Adam, A. Agarwal +46 more
2021Clinical Cancer Research49 citations Open access
Semantic Scholar
Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies
Joshua Richter, S. Thomas, Amrita Y. Krishnan, Jacob P. Laubach +16 more
2024Blood41 citations
Semantic Scholar
Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma
N. Raje, N. Bahlis, C. Costello, B. Dholaria +15 more
2022Blood41 citations Open access
Semantic Scholar
Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity
S. Trudel, N. Bahlis, A. Spencer, R. Kaedbey +8 more
2022Blood40 citations Open access
Semantic Scholar
Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial
S. Trudel, A. Mccurdy, M. Louzada, Stephen Parkin +9 more
2024Nature Medicine37 citations Open access
Semantic Scholar
Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort
S. Grosicki, U. Mellqvist, Łukasz Pruchniewski, Jacob Crafoord +11 more
2022Blood28 citations Open access
Semantic Scholar
Antibodies and bispecifics for multiple myeloma: effective effector therapy.
Christopher Cipkar, Christine Chen, S. Trudel
2022Hematology. American Society of Hematology. Education Program27 citations Open access
Semantic Scholar
Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial
A. Nooka, A. Cohen, Hans C. Lee, A. Badros +19 more
2022Blood24 citations Open access
Semantic Scholar
Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial
P. Richardson, S. Trudel, H. Quach, R. Popat +15 more
2022Blood21 citations Open access
Semantic Scholar
Part 1 Results of a Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
S. Trudel, A. Mccurdy, H. Sutherland, M. Louzada +9 more
2021Blood21 citations Open access
Semantic Scholar
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
Pralay Mukhopadhyay, Hesham A. Abdullah, J. Opalinska, P. Paka +6 more
2025Blood Cancer Journal17 citations Open access
Semantic Scholar
Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1.
A. Jakubowiak, N. Bahlis, N. Raje, C. Costello +16 more
2022Journal of Clinical Oncology16 citations
Semantic Scholar
Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma
S. Trudel, A. Mccurdy, Molei Fu, H. Sutherland +9 more
2022Blood14 citations Open access
Semantic Scholar
DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma
N. Callander, V. Ribrag, P. Richardson, A. Nooka +12 more
2021Blood12 citations Open access
Semantic Scholar
Myeloma immunoglobulin rearrangement and translocation detection through targeted capture sequencing
Signy Chow, Olena Kis, D. Mulder, A. Danesh +9 more
2022Life Science Alliance11 citations Open access
Semantic Scholar
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).
S. Trudel, M. Beksaç, L. Pour, S. Delimpasi +14 more
2024Journal of Clinical Oncology9 citations Open access
Semantic Scholar
EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
M. Solh, N. Bahlis, N. Raje, C. Costello +16 more
2021Hematology, Transfusion and Cell Therapy9 citations Open access
Semantic Scholar
Tumor clearance, T-cell fitness, and minimal residual disease (MRD) outcomes in patients with relapsed/refractory multiple myeloma (RRMM) treated with cevostamab plus pomalidomide and dexamethasone: Biomarker analyses from CAMMA 1 Arm B
Simon J. Harrison, Caroline Hasselbalch Riley, H. Mian, Andrew Spencer +15 more
2025Blood8 citations
Semantic Scholar
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial
Adam D. Cohen, Joshua Richter, S. Trudel, A. Lesokhin +20 more
2026Nature Medicine7 citations Open access
Semantic Scholar
A Belantamab Mafodotin Revival in Multiple Myeloma Therapy.
S. Trudel, A. K. Stewart
2024New England Journal of Medicine7 citations
Semantic Scholar
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide
M. Beksaç, E. González García, S. Delimpasi, P. Robak +26 more
2024Blood7 citations
Semantic Scholar
Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma
A. Suvannasankha, Nizar J. Bahlis, S. Trudel, K. Weisel +16 more
2024Cancer7 citations Open access
Semantic Scholar
The Impact of CD34+ Cell Collection Yields for Autologous Transplant on Survival Outcomes in Multiple Myeloma.
E. Lebel, K. Lajkosz, E. Masih-Khan, D. Reece +5 more
2023Clinical Lymphoma, Myeloma & Leukemia7 citations
Semantic Scholar
Single-cell profiling of multiple myeloma reveals molecular response to FGFR3 inhibitor despite clinical progression
Danielle C. Croucher, A. Devasia, D. Abelman, A. Mahdipour-Shirayeh +5 more
2023Cold Spring Harbor molecular case studies7 citations Open access
Semantic Scholar
Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up
Saad Z. Usmani, Shaji K. Kumar, M. Mateos, J. C. Ye +32 more
2025Blood6 citations
Semantic Scholar
CAMMA 1: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of cevostamab-containing regimens in patients with relapsed or refractory multiple myeloma.
R. Vij, H. Schade, S. Trudel, A. Chang +6 more
2022Journal of Clinical Oncology6 citations
Semantic Scholar
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative.
Tess Aalto, M. Abacan, S. Abadi, F. Aghababazadeh +496 more
2025Cancer Cell5 citations
Semantic Scholar
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial.
M. Dimopoulos, M. Beksaç, L. Pour, S. Delimpasi +23 more
2025The Lancet Haematology5 citations
Semantic Scholar
Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial
A. Mccurdy, Donna Reece, M. Louzada, D. White +9 more
2024Blood Cancer Journal5 citations Open access
Semantic Scholar
Safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-4 Study.
A. Suvannasankha, N. Bahlis, S. Trudel, K. Weisel +14 more
2022Journal of Clinical Oncology5 citations
Semantic Scholar
Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study
S. Trudel, M. Beksaç, L. Pour, S. Delimpasi +21 more
2025Blood4 citations
Semantic Scholar
PIKfyve inhibition in MM disrupts autophagy and lysosome function, increasing MHC expression and cholesterol metabolism
Cecilia Bonolo de Campos, Ruijuan He, Tessa Pelino, D. Abelman +15 more
2025Blood4 citations
Semantic Scholar
P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL
A. Nooka, A. Cohen, H. Lee, A. Badros +19 more
2023HemaSphere4 citations Open access
Semantic Scholar
P946: TOCILIZUMAB PRE-TREATMENT SIGNIFICANTLY REDUCES THE INCIDENCE OF CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE CEVOSTAMAB
M. Mateos, N. Bahlis, A. Spencer, R. Kaedbey +8 more
2023HemaSphere4 citations Open access
Semantic Scholar
Post Salvage Therapy Autologous Transplant for Relapsed Myeloma, Ongoing Relevance within Modern Treatment Paradigms?
Sahar Khan, D. Reece, E. Atenafu, S. Bhella +7 more
2022Clinical Lymphoma, Myeloma & Leukemia4 citations
Semantic Scholar
MM-379: MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM)
M. Levy, N. Bahlis, N. Raje, C. Costello +16 more
20214 citations
Semantic Scholar
Biomarker Analyses of the CC-92480-MM-001 Trial to Guide Combinatorial Strategies for Mezigdomide
Tracy T. Chow, Nicholas Stong, Saleh Tamim, Chad C. Bjorklund +12 more
2024Blood3 citations
Semantic Scholar
Cell-Free DNA Whole Genome Sequencing for Non-Invasive MRD Detection in Multiple Myeloma
D. Abelman, Jenna Eagles, A. Wong, Saumil Shah +13 more
2024Blood3 citations
Semantic Scholar
Survival and Renal Recovery in Newly Diagnosed Multiple Myeloma Patients Presenting With Dialysis‐Requiring Severe Renal Impairment
Rintu Sharma, E. Atenafu, E. Masih-Khan, H. Vohra +10 more
2026European Journal of Haematology2 citations Open access
Semantic Scholar
Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma
Rintu Sharma, Andree-Anne Pelland, K. Lajkosz, E. Masih-Khan +10 more
2026Blood Cancer Discovery2 citations Open access
Semantic Scholar
Impact of tumor burden on the risk of cytokine release syndrome (CRS) in patients with multiple myeloma treated with elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) in the MagnetisMM-6 trial
C. Touzeau, H. Sia, S. Grosicki, P. Ribas +10 more
2025Blood2 citations
Semantic Scholar
Impact of renal impairment (RI) on pharmacokinetics (PK) and clinical outcomes with mezigdomide plus dexamethasone (DEX) in relapsed/refractory multiple myeloma (RRMM).
S. Trudel, Nizar J. Bahlis, R. Popat, María-Victoria Mateos +15 more
2024Journal of Clinical Oncology2 citations Open access
Semantic Scholar
Phase II Study of Isatuximab, and Weekly Carfilzomib + Dexamethasone in Relapsed and Refractory Multiple Myeloma (RRMM)
D. Vesole, T. Martin, S. Trudel, H. Schade +7 more
2024Blood2 citations
Semantic Scholar
Cell-Free DNA from Blood or Bone Marrow as Alternatives to Bone Marrow Cells for Molecular Diagnostics and Monitoring of Multiple Myeloma
D. Abelman, Jenna Eagles, S. Pedersen, A. Danesh +9 more
2023Blood2 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

N. Bahlis×13
Invite
N. Bahlis — researcher profile on SciRah
H. Quach×9
Invite
H. Quach — researcher profile on SciRah
S. Lonial×8
Invite
S. Lonial — researcher profile on SciRah
R. Popat×7
Invite
R. Popat — researcher profile on SciRah

×7

Invite

M. Mateos — researcher profile on SciRah

María-Victoria Mateos×6

Invite

María-Victoria Mateos — researcher profile on SciRah

A. Jakubowiak×6

Invite

A. Jakubowiak — researcher profile on SciRah

Invite

M. Sebag — researcher profile on SciRah

Invite

A. Lesokhin — researcher profile on SciRah

Invite

D. Reece — researcher profile on SciRah

Invite

M. Beksaç — researcher profile on SciRah

S. Delimpasi×5

Invite

S. Delimpasi — researcher profile on SciRah